Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer

被引:55
|
作者
Sun, Zhifei [1 ]
Adam, Mohamed A. [1 ]
Kim, Jina [1 ]
Nussbaum, Daniel P. [1 ]
Benrashid, Ehsan [1 ]
Mantyh, Christopher R. [1 ]
Migaly, John [1 ]
机构
[1] Duke Univ, Dept Surg, Durham, NC USA
关键词
Colon cancer; Adjuvant chemotherapy; Optimal timing; Outcomes; COLORECTAL-CANCER; SURVIVAL; THERAPY; FLUOROURACIL; OXALIPLATIN; LEVAMISOLE; SURGERY; IMPACT; DELAY;
D O I
10.1097/DCR.0000000000000518
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Several reports suggest that the efficacy of adjuvant chemotherapy on survival diminishes over time for colon cancer; however, precise timing of its loss of benefit has not been established. OBJECTIVE: This study aimed to determine the relationship between time to adjuvant chemotherapy and survival and to identify a threshold for increased risk of mortality. DESIGN: This was a retrospective study. Multivariable Cox proportional hazard modeling with restricted cubic splines was used to evaluate the adjusted association between time to adjuvant chemotherapy and overall survival and to establish an optimal threshold for the initiation of therapy. SETTINGS: Data were collected from the National Cancer Data Base. PATIENTS: Adults who received adjuvant chemotherapy following resection of stage II to II colon cancers were selected. MAIN OUTCOME MEASURES: The primary outcome measured was overall survival. RESULTS: A total of 7794 patients were included. After adjusting for clinical, tumor, and treatment characteristics, our model determined a critical threshold of chemotherapy initiation at 44 days from surgery, after which there was an increase in the overall mortality. At a median follow-up of 61 months, the risk of mortality was increased in those who received adjuvant chemotherapy after 44 days from surgery (adjusted HR, 1.14; 95% CI, 1.05-1.24; p = 0.002), but not in those who received chemotherapy before 44 days from surgery (p = 0.11). Each additional week of delay was associated with a 7% decrease in survival (HR, 1.07; 95% CI, 1.04-1.10; p < 0.001). LIMITATIONS: This study was limited by selection bias and the inability to compare specific chemotherapy regimens. CONCLUSIONS: This study objectively determines the optimal timing of adjuvant chemotherapy for patients with resected colon cancer. Delay beyond 6 weeks is associated with compromised survival. These findings emphasize the importance of the timely initiation of therapy, and suggest that efforts to enhance recovery following surgery have the potential to improve survival by decreasing delay to adjuvant chemotherapy.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [41] Adjuvant chemotherapy for stage II and stage III colon cancer-What is happening in routine practice?
    Ananda, S.
    Kosmider, S.
    Lim, L.
    Barnett, F.
    Desai, J.
    Gibbs, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
    Peng Gao
    Xuan-zhang Huang
    Yong-xi Song
    Jing-xu Sun
    Xiao-wan Chen
    Yu Sun
    Yu-meng Jiang
    Zhen-ning Wang
    [J]. BMC Cancer, 18
  • [43] Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
    Gao, Peng
    Huang, Xuan-zhang
    Song, Yong-xi
    Sun, Jing-xu
    Chen, Xiao-wan
    Sun, Yu
    Jiang, Yu-meng
    Wang, Zhen-ning
    [J]. BMC CANCER, 2018, 18
  • [44] Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer
    Kadakia, Kunal C.
    Worrilow, William M.
    Coley, Harris
    Salem, Mohammed E.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 289 - 298
  • [45] Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal Cancer
    Cheung, Winson Y.
    Neville, Bridget A.
    Earle, Craig C.
    [J]. DISEASES OF THE COLON & RECTUM, 2009, 52 (06) : 1054 - 1063
  • [46] Adjuvant chemotherapy for stages II, III and IV of colon cancer
    Gravalos, Cristina
    Garcia-Escobar, Ignacio
    Garcia-Alfonso, Pilar
    Cassinello, Javier
    Malon, Diego
    Carrato, Alfredo
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (08): : 526 - 533
  • [47] Adjuvant chemotherapy for stages II, III and IV of colon cancer
    Cristina Grávalos
    Ignacio García-Escobar
    Pilar García-Alfonso
    Javier Cassinello
    Diego Malón
    Alfredo Carrato
    [J]. Clinical and Translational Oncology, 2009, 11 : 526 - 533
  • [48] Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma
    Kannarkatt, Joseph
    Joseph, Joe
    Kurniali, Peter C.
    Al-Janadi, Anas
    Hrinczenko, Borys
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (04) : 233 - +
  • [49] Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer
    Koenig, Julie L.
    Toesca, Diego A. S.
    Harris, Jeremy P.
    Tsai, Chiaojung Jillian
    Haraldsdottir, Sigurdis
    Lin, Albert Y.
    Pollon, Erqi L.
    Chang, Daniel T.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (07): : 573 - 580
  • [50] Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On
    Lee, James J.
    Chu, Edward
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (04) : 245 - +